XML 88 R51.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | $ 22,449 | $ 22,127 | $ 26,107
Revenues | $ 5,879 | $ 5,604 | $ 5,685 | $ 5,281 | $ 5,795 | $ 5,596 | $ 5,648 | $ 5,088 | 22,449 | 22,127 | 26,107
U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 16,645 | 16,269 | 18,194
Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 3,811 | 4,006 | 5,311
Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,993 | 1,852 | 2,602
Atripla |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 600 | 1,206 | 1,806
Atripla | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 501 | 967 | 1,288
Atripla | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 60 | 131 | 335
Atripla | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 39 | 108 | 183
Biktarvy |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 4,738 | 1,184 | 0
Biktarvy | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 4,225 | 1,144 | 0
Biktarvy | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 370 | 39 | 0
Biktarvy | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 143 | 1 | 0
Complera/Eviplera |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 406 | 653 | 966
Complera/Eviplera | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 160 | 276 | 406
Complera/Eviplera | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 214 | 327 | 503
Complera/Eviplera | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 32 | 50 | 57
Descovy |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,500 | 1,581 | 1,218
Descovy | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,078 | 1,217 | 958
Descovy | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 255 | 308 | 226
Descovy | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 167 | 56 | 34
Genvoya |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 3,931 | 4,624 | 3,674
Genvoya | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 2,984 | 3,631 | 3,033
Genvoya | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 664 | 794 | 534
Genvoya | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 283 | 199 | 107
Odefsey |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,655 | 1,598 | 1,106
Odefsey | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,180 | 1,242 | 964
Odefsey | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 438 | 335 | 132
Odefsey | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 37 | 21 | 10
Stribild |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 369 | 644 | 1,053
Stribild | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 268 | 505 | 811
Stribild | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 75 | 97 | 195
Stribild | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 26 | 42 | 47
Truvada |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 2,813 | 2,997 | 3,134
Truvada | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 2,640 | 2,605 | 2,266
Truvada | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 101 | 260 | 644
Truvada | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 72 | 132 | 224
Other HIV |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 47 | 61 | 58
Other HIV | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 30 | 40 | 43
Other HIV | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 5 | 7 | 6
Other HIV | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 12 | 14 | 9
Revenue share - Symtuza |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 379 | 79 | 0
Revenue share - Symtuza | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 249 | 27 | 0
Revenue share - Symtuza | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 130 | 52 | 0
Revenue share - Symtuza | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 0 | 0 | 0
AmBisome |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 407 | 420 | 366
AmBisome | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 37 | 46 | 28
AmBisome | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 234 | 229 | 207
AmBisome | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 136 | 145 | 131
Ledipasvir/Sofosbuvir |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 643 | 1,222 | 4,370
Ledipasvir/Sofosbuvir | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 312 | 802 | 3,053
Ledipasvir/Sofosbuvir | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 71 | 144 | 704
Ledipasvir/Sofosbuvir | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 260 | 276 | 613
Letairis |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 618 | 943 | 887
Letairis | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 618 | 943 | 887
Letairis | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 0 | 0 | 0
Letairis | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 0 | 0 | 0
Ranexa |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 216 | 758 | 717
Ranexa | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 216 | 758 | 717
Ranexa | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 0 | 0 | 0
Ranexa | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 0 | 0 | 0
Sofosbuvir/Velpatasvir |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,965 | 1,966 | 3,510
Sofosbuvir/Velpatasvir | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 971 | 934 | 2,404
Sofosbuvir/Velpatasvir | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 553 | 654 | 869
Sofosbuvir/Velpatasvir | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 441 | 378 | 237
Vemlidy |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 488 | 321 | 122
Vemlidy | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 309 | 245 | 111
Vemlidy | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 21 | 12 | 5
Vemlidy | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 158 | 64 | 6
Viread |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 243 | 307 | 1,046
Viread | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 32 | 50 | 514
Viread | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 69 | 82 | 238
Viread | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 142 | 175 | 294
Vosevi |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 257 | 396 | 293
Vosevi | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 178 | 304 | 267
Vosevi | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 54 | 78 | 22
Vosevi | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 25 | 14 | 4
Yescarta |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 456 | 264 | 7
Yescarta | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 373 | 263 | 7
Yescarta | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 83 | 1 | 0
Yescarta | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 0 | 0 | 0
Zydelig |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 103 | 133 | 149
Zydelig | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 47 | 61 | 69
Zydelig | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 54 | 70 | 77
Zydelig | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 2 | 2 | 3
Other(3) |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 285 | 320 | 1,180
Other(3) | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 157 | 137 | 283
Other(3) | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 116 | 76 | 314
Other(3) | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 12 | 107 | 583
Product sales |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 22,119 | 21,677 | 25,662
Product sales | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 16,565 | 16,197 | 18,109
Product sales | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 3,567 | 3,696 | 5,011
Product sales | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,987 | 1,784 | 2,542
Royalty, contract and other revenues |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 330 | 450 | 445
Revenues |  |  |  |  |  |  |  |  | 330 | 450 | 445
Royalty, contract and other revenues | U.S. |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 80 | 72 | 85
Royalty, contract and other revenues | Europe |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 244 | 310 | 300
Royalty, contract and other revenues | Other International |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | $ 6 | $ 68 | $ 60

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |